211 related articles for article (PubMed ID: 29175173)
1. Diagnostic and clinical significance of the titin fragment in urine of Duchenne muscular dystrophy patients.
Awano H; Matsumoto M; Nagai M; Shirakawa T; Maruyama N; Iijima K; Nabeshima YI; Matsuo M
Clin Chim Acta; 2018 Jan; 476():111-116. PubMed ID: 29175173
[TBL] [Abstract][Full Text] [Related]
2. Dramatic elevation in urinary amino terminal titin fragment excretion quantified by immunoassay in Duchenne muscular dystrophy patients and in dystrophin deficient rodents.
Robertson AS; Majchrzak MJ; Smith CM; Gagnon RC; Devidze N; Banks GB; Little SC; Nabbie F; Bounous DI; DiPiero J; Jacobsen LK; Bristow LJ; Ahlijanian MK; Stimpson SA
Neuromuscul Disord; 2017 Jul; 27(7):635-645. PubMed ID: 28554556
[TBL] [Abstract][Full Text] [Related]
3. Receiver operating curve analyses of urinary titin of healthy 3-y-old children may be a noninvasive screening method for Duchenne muscular dystrophy.
Matsuo M; Shirakawa T; Awano H; Nishio H
Clin Chim Acta; 2018 Nov; 486():110-114. PubMed ID: 30053403
[TBL] [Abstract][Full Text] [Related]
4. Proteomics profiling of urine reveals specific titin fragments as biomarkers of Duchenne muscular dystrophy.
Rouillon J; Zocevic A; Leger T; Garcia C; Camadro JM; Udd B; Wong B; Servais L; Voit T; Svinartchouk F
Neuromuscul Disord; 2014 Jul; 24(7):563-73. PubMed ID: 24813925
[TBL] [Abstract][Full Text] [Related]
5. A sandwich ELISA kit reveals marked elevation of titin N-terminal fragment levels in the urine of mdx mice.
Shirakawa T; Ikushima A; Maruyama N; Nambu Y; Awano H; Osawa K; Nirasawa K; Negishi Y; Nishio H; Fukushima S; Matsuo M
Animal Model Exp Med; 2022 Feb; 5(1):48-55. PubMed ID: 35229992
[TBL] [Abstract][Full Text] [Related]
6. Urinary titin as a biomarker in Fukuyama congenital muscular dystrophy.
Sato T; Awano H; Ishiguro K; Shichiji M; Murakami T; Shirakawa T; Matsuo M; Nagata S; Ishigaki K
Neuromuscul Disord; 2021 Mar; 31(3):194-197. PubMed ID: 33563515
[TBL] [Abstract][Full Text] [Related]
7. Can urinary titin be used for predicting Duchenne muscular dystrophy?
Matsuo M; Awano H; Nishio H
Clin Chim Acta; 2019 Mar; 490():162. PubMed ID: 30395868
[No Abstract] [Full Text] [Related]
8. Urine titin as a novel biomarker for Duchenne muscular dystrophy.
Ishii MN; Nakashima M; Kamiguchi H; Zach N; Kuboki R; Baba R; Hirakawa T; Suzuki K; Quinton M
Neuromuscul Disord; 2023 Apr; 33(4):302-308. PubMed ID: 36871413
[TBL] [Abstract][Full Text] [Related]
9. Can urinary titin be used for predicting Duchenne muscular dystrophy?
Bai SM; Guo XX
Clin Chim Acta; 2019 Mar; 490():161. PubMed ID: 30391395
[No Abstract] [Full Text] [Related]
10. Titin fragment in urine: A noninvasive biomarker of muscle degradation.
Matsuo M; Awano H; Maruyama N; Nishio H
Adv Clin Chem; 2019; 90():1-23. PubMed ID: 31122607
[TBL] [Abstract][Full Text] [Related]
11. Establishment of a highly sensitive sandwich ELISA for the N-terminal fragment of titin in urine.
Maruyama N; Asai T; Abe C; Inada A; Kawauchi T; Miyashita K; Maeda M; Matsuo M; Nabeshima YI
Sci Rep; 2016 Dec; 6():39375. PubMed ID: 27991570
[TBL] [Abstract][Full Text] [Related]
12. A prostaglandin D2 metabolite is elevated in the urine of Duchenne muscular dystrophy patients and increases further from 8 years old.
Nakagawa T; Takeuchi A; Kakiuchi R; Lee T; Yagi M; Awano H; Iijima K; Takeshima Y; Urade Y; Matsuo M
Clin Chim Acta; 2013 Aug; 423():10-4. PubMed ID: 23603101
[TBL] [Abstract][Full Text] [Related]
13. [Changes of serum creatine kinase levels in children with Duchenne muscular dystrophy].
Sun SC; Peng YS; He JB
Zhongguo Dang Dai Er Ke Za Zhi; 2008 Feb; 10(1):35-7. PubMed ID: 18289468
[TBL] [Abstract][Full Text] [Related]
14. The L-arginine/NO pathway and homoarginine are altered in Duchenne muscular dystrophy and improved by glucocorticoids.
Hörster I; Weigt-Usinger K; Carmann C; Chobanyan-Jürgens K; Köhler C; Schara U; Kayacelebi AA; Beckmann B; Tsikas D; Lücke T
Amino Acids; 2015 Sep; 47(9):1853-63. PubMed ID: 26066683
[TBL] [Abstract][Full Text] [Related]
15. N-terminal titin fragment: a non-invasive, pharmacodynamic biomarker for microdystrophin efficacy.
Boehler JF; Brown KJ; Ricotti V; Morris CA
Skelet Muscle; 2024 Jan; 14(1):2. PubMed ID: 38229112
[TBL] [Abstract][Full Text] [Related]
16. Serum miR-206 and other muscle-specific microRNAs as non-invasive biomarkers for Duchenne muscular dystrophy.
Hu J; Kong M; Ye Y; Hong S; Cheng L; Jiang L
J Neurochem; 2014 Jun; 129(5):877-83. PubMed ID: 24460924
[TBL] [Abstract][Full Text] [Related]
17. Urinary N-terminal fragment of titin is a marker to diagnose muscular dystrophy in patients with cardiomyopathy.
Yoshihisa A; Kiko T; Sato T; Oikawa M; Kobayashi A; Takeishi Y
Clin Chim Acta; 2018 Sep; 484():226-230. PubMed ID: 29870683
[TBL] [Abstract][Full Text] [Related]
18. Urinary prostaglandin metabolites as Duchenne muscular dystrophy progression markers.
Takeshita E; Komaki H; Tachimori H; Miyoshi K; Yamamiya I; Shimizu-Motohashi Y; Ishiyama A; Saito T; Nakagawa E; Sugai K; Sasaki M
Brain Dev; 2018 Nov; 40(10):918-925. PubMed ID: 30006121
[TBL] [Abstract][Full Text] [Related]
19. Renal function in children and adolescents with Duchenne muscular dystrophy.
Braat E; Hoste L; De Waele L; Gheysens O; Vermeersch P; Goffin K; Pottel H; Goemans N; Levtchenko E
Neuromuscul Disord; 2015 May; 25(5):381-7. PubMed ID: 25683700
[TBL] [Abstract][Full Text] [Related]
20. Genetic and Early Clinical Manifestations of Females Heterozygous for Duchenne/Becker Muscular Dystrophy.
Papa R; Madia F; Bartolomeo D; Trucco F; Pedemonte M; Traverso M; Broda P; Bruno C; Zara F; Minetti C; Fiorillo C
Pediatr Neurol; 2016 Feb; 55():58-63. PubMed ID: 26718981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
